Valeo Pharma (CSE: VPH) CEO Steve Saviuk joined Steve Darling from Proactive Vancouver with news the company has closed its previously announced bought deal offering and along with the exercise in full of the Underwriters’ over-allotment option of 750,000 additional Units, the company has topped up the treasury with 6.9 million dollars.

Saviuk shares with Proactive where the capital is expected to be deployed and he also shares his thoughts on the approval of the immune system boosting product Hesperco from Health Canada.